One study reported an αvβ3-targeted 177Lu-labeled cyclo[RGDfk] (“177Lu-EB-RGD”), which was modified with an albumin-binding domain to increase blood half-life and tumor accumulation [429]. This evidence concerns the gene ALB and neoplasm.